Strachan D P, Griffiths J M, Johnston I D, Anderson H R
Department of Public Health Science, St. George's Hospital Medical School, London, United Kingdom.
Am J Respir Crit Care Med. 1996 Dec;154(6 Pt 1):1629-35. doi: 10.1164/ajrccm.154.6.8970346.
The impact of past and current asthma on ventilatory function was assessed among young adults born in Britain March 3-9, 1958 who had been followed from birth to ages 7, 11, 16, 23, and 33 yr. We compared 1,060 subjects with a history of asthma, wheezy bronchitis, or wheezing with 275 control subjects with no history of chest illness. Forced expiratory volume in one second (FEV1) and forced vital capacity (FVC) were measured at 34-35 yr of age before and 20 min after inhalation of 400 micrograms salbutamol, and adjusted for sex, height, and smoking by multiple regression. Among 551 cases reporting no wheeze in the year before examination, ventilatory function after salbutamol did not differ significantly from the controls, except for FEV1 in 192 subjects with transient wheezing before age 7 (p < 0.05). Among 509 cases reporting wheeze in the past year, FEV1 and FEV1/FVC ratio were reduced to a greater extent in those with an earlier age of onset of wheeze (p < 0.001 for trend in each case). These relative reductions were greater if wheezing had persisted through childhood and adolescence, and were only partially reversed by inhalation of salbutamol. Progressive pulmonary changes related to chronic asthma may be an important mechanism underlying the association between childhood chest illnesses and chronic respiratory disease in adult life.
在1958年3月3日至9日出生于英国、从出生起就被跟踪至7岁、11岁、16岁、23岁和33岁的年轻人中,评估过去和当前哮喘对通气功能的影响。我们将1060名有哮喘、喘息性支气管炎或喘息病史的受试者与275名无胸部疾病史的对照受试者进行了比较。在34 - 35岁时,在吸入400微克沙丁胺醇之前和之后20分钟测量一秒用力呼气量(FEV1)和用力肺活量(FVC),并通过多元回归对性别、身高和吸烟情况进行校正。在551例在检查前一年报告无喘息的病例中,除了192名在7岁前有短暂喘息的受试者的FEV1外(p < 0.05),沙丁胺醇治疗后的通气功能与对照组无显著差异。在509例过去一年报告有喘息的病例中,喘息发病年龄较早者的FEV1和FEV1/FVC比值降低程度更大(每种情况的趋势p < 0.001)。如果喘息在儿童期和青春期持续存在,这些相对降低幅度会更大,并且吸入沙丁胺醇只能部分逆转。与慢性哮喘相关的进行性肺部改变可能是儿童期胸部疾病与成年期慢性呼吸道疾病之间关联的重要潜在机制。